Novo Nordisk's amycretin has shown promise in a phase 2 diabetes trial, with reports indicating it can help reduce body weight and lower blood sugar. The results have been described as "remarkable" and may support progression to phase 3 trials. Some outlets have also noted the potential of amycretin as a weight loss treatment, with one report citing weight loss of up to 13% after three months.